药智论坛

查看: 816|回复: 0

Comparison of effectiveness and adverse effects of gefitinib,erlotinib and ic...

[复制链接]
发表于 2018-9-29 15:30:04 | 显示全部楼层 |阅读模式 来自 重庆
Comparison of effectiveness and adverse effects of gefitinib,erlotinib and icotinib among patients with non‑smallcell lung cancer: A network meta‑analysis




Abstract. The present network meta-analysis aimed to compare the effectiveness and adverse effects of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer (NSCLC). Two reviewers searched the Cochrane, PubMed, Embase, ScienceDirect, China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals and Wanfang databases for relevant studies. Studies were thenscreened and evaluated, and data was extracted. End‑points evaluated for NSCLC included complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), overall response rate (ORR), disease control rate (DCR), progression‑free survival (PFS), median survival time (MST) and adverse effects, including rash, diarrhea, nausea and vomiting, fatigue and abnormal liver function. For the analysis of incorporated studies, RevMan, SPSS, R and Stata software were used. A total of 43 studies with 7,168 patients were included in the network meta‑analysis. No significant differences were observed in CR, PR, SD, PD, ORR or DCR between gefitinib, erlotinib and icotinib by using network meta analysis.
Compared with gefitinib, erlotinib resulted in a higher rate of nausea and vomiting [adjusted odds ratio (OR)=2.0; 95% credible interval, 1.1‑3.7]. However, no significant differences were observed in the rates of rash, diarrhea, fatigue or abnormal liver function using network meta‑analysis. Compared with erlotinib, gefitinib resulted in a lower SD rate [OR=0.86; 95%


etm_14_5_4017_PDF.pdf (2.17 MB, 下载次数: 0)
您需要登录后才可以回帖 登录 | 免费注册

本版积分规则

QQ|论坛规则|(渝)-经营性-2021-0017|渝B2-20120028|前往 违法和不良信息举报中心 举报|药智论坛 ( 渝ICP备10200070号-7

渝公网安备 50010802004459号

GMT+8, 2024-3-28 22:42

快速回复 返回顶部 返回列表